Karyopharm Therapeutics logo

Karyopharm Therapeutics

Brand · Pharmaceutical Manufacturing

3.9

Company overview

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As an organization, Karyopharm is on a mission to improve lives and defeat cancer. In its role as leaders in XPO1 inhibition, Karyopharm delivers on its mission by creating a focused pipeline that targets multiple high unmet need cancer indications, including multiple myeloma, endometrial cancer,myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).
Founded in 2008
Newton Centre, Massachusetts, USA
312 employees (6 in marketing)
www.karyopharm.com
77% recommend to a friend
65% positive business outlook

Salaries

Typical salary range

$270,000 – $315,000

/ yr

Help build salary transparency at Karyopharm Therapeutics

Share your compensation anonymously to see full data.

Contribute

People

Founders

Richard Paulson
Richard Paulson
President and Chief Executive Officer
LinkedIn
Sharon Shacham
Sharon Shacham
Founder
LinkedIn
Michael Kauffman
Michael Kauffman
Cofounder
LinkedIn

Marketing leadership

Lisa Shrayer
Lisa Shrayer
Executive Director, Brand Counsel
LinkedIn
Zachary Babbe
Zachary Babbe
Senior Director, HCP Marketing
LinkedIn
Chris Tomaso
Chris Tomaso
Executive Director, Peer-to-Peer Marketing & Commercial Effectiveness
LinkedIn

Hiring contacts

Lisa A. DiPaolo
Lisa A. DiPaolo
EVP, Chief Human Resources Officer (CHRO)
LinkedIn
Dylan Leonard Brown, SHRM-CP
Dylan Leonard Brown, SHRM-CP
Director, HR Business Partner & Head of Talent Acquisition
LinkedIn
Alex Gonzales
Alex Gonzales
Executive Director, HR Business Partner & Head of Talent Management
LinkedIn

Hiring activity

Open marketing jobs over time

3 open now

Headcount trend

Company growth over the last 12 months

Headcount -12.1% year over year

Funding

Total funding

$637.2M

Last raise

$30M

Post IPO Equity, 3 months ago

Funding history

Mar 2026

Post IPO Equity Karyopharm Therapeutics · $30M

Oct 2025

Post IPO Equity Karyopharm Therapeutics · $33M

Oct 2025

Post IPO Debt Karyopharm Therapeutics · $27.5M

Dec 2022

Post IPO Equity Karyopharm Therapeutics · $165M

Mar 2020

Post IPO Equity Karyopharm Therapeutics · $172.5M

Jun 2014

Post IPO Equity Karyopharm Therapeutics · $111M

Audience

Monthly website visitors
8.9K
Month over month-5.5%
Quarter over quarter+43.7%
Top sourceDirect (44.4%)
Ad budget per month$0.0
Average search rank51.7
Traffic source mix
Direct
44.4%
Search
38.5%
Social
9.3%
Referral
6.4%
Paid referral
1.3%

LinkedIn followers

Follower count and growth

Total followers

36.8K

12-mo growth

+9.1%

Monthly growth

+1.2%

News

Links

www.karyopharm.comLinkedInCrunchbaseX (Twitter)
Glassdoor